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Introduction {#sec005}
============

End-stage renal disease (ESRD) is a chronic and progressive decline in kidney function, which will eventually lead to uremia and death if it is not treated properly \[[@pone.0169203.ref001]\]. However, with a progress of technology in past decades, the mortality have not improved significantly and exceeding 20% in chronic hemodialysis patients \[[@pone.0169203.ref002], [@pone.0169203.ref003]\]. Cardiovascular events are the main driving force for this high mortality. Therefore, there is a need for new methods to improve ESRD patients' cardiovascular and mortality risk.

There are currently two main methods for treatment of ESRD patients. The first, renal transplantation, is a permanent method to cure ESRD patients, however, that means ESRD patients have an issue of having a proper kidney source, thus it has limited application \[[@pone.0169203.ref004], [@pone.0169203.ref005]\]. The second, hemodialysis, is applied worldwide but has a high risk of cardiovascular complications and significantly reduces the quality of life of patients \[[@pone.0169203.ref006], [@pone.0169203.ref007]\]. Nocturnal hemodialysis (NHD) is an important branch of hemodialysis \[[@pone.0169203.ref008], [@pone.0169203.ref009]\]. The schedule for nocturnal dialysis is 3--7 times per week, 7--8 hours every time. This approach extends the effective duration of dialysis without affecting the patient's daytime activities making it more convenient as a method of treatment. This approach has been widely used in Canada; however, the clinical results still require further examination. Dialysis-related disease is defined as the complications caused by long-term dialysis on ESRD patients; cardiovascular disease is the leading cause of death for ESRD patients \[[@pone.0169203.ref010]--[@pone.0169203.ref013]\].

Previously, several systemic reviews analyzed the mortality, blood pressure, and urinary-related indexes of NHD for ESRD patients \[[@pone.0169203.ref014]--[@pone.0169203.ref016]\]. However, the qualities of included studies were relatively low and not comprehensive evaluated all relevant clinical outcomes. Our research is up to date with recently published research and analyzes the effects of NHD by mortality, cardiovascular-related variables, uremia-related variables, quality of life, side-effects, and drug usage to provide better insight in clinical choices for dialysis methods.

Methods {#sec006}
=======

Search strategy and selection criteria {#sec007}
--------------------------------------

This review was conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Statement \[[@pone.0169203.ref017]\] issued in 2009. Any studies that examined NHD versus conventional hemodialysis (CHD) on ESRD patients were eligible for inclusion in our study with no restrictions placed on language or publication status (published, or in press). We searched the Medline, EmBase, and Cochrane Library electronic databases for articles published through January 2016 and used "nocturnal", "dialysis", "hemodialysis", and "controlled trials" as the search keywords. We also conducted manual searches of reference lists from all relevant original articles and reviews to identify additional eligible studies.

A literature search was undertaken independently by 2 authors and any inconsistencies were settled via group discussion. A study was eligible for inclusion if the following criteria were met: (1) the trial investigated nocturnal hemodialysis NHD versus conventional hemodialysis CHD; (2) all of patients included with ESRD; and (3) the outcomes variable included one of the following: mortality, cardiovascular-associated variables, uremia-associated variables, quality of life, side-effect, and drug usage. Case series, reviews, and editorials were excluded.

Data collection and quality assessment {#sec008}
--------------------------------------

Two reviewers independently extracted all data with disagreements resolved in consultation with third-party investigators. The following items were extracted from the included articles: first author, publication year, country, location or data source, study design, sample size, disease status, mean age, gender proportion, mean duration of dialysis, Dialysis session, and reported outcomes. The outcome assessments included: mortality, cardiovascular-associated variables, uremia-associated variables, quality of life, side-effects, and drug usage. In analysis, the numerical changes between, before, and after dialysis of statistical indicators had priority to be adopted, if not, the dialysis numerical indicators after dialysis was adopted. In addition, the numerical units were adjusted for consistency, such as g/L and g/dL. Two reviewers independently assessed the quality of included studies according to the Cochrane risk of bias tool in the following six domains: selection, performance, detection, attrition, reporting and other bias \[[@pone.0169203.ref018]\].

Statistical analysis {#sec009}
--------------------

For our meta-analysis, we used the inverse variance method to pool continuous data and the Mantel-Haenszel method for dichotomous data; the results are presented as standardized mean difference (SMD) with 95% confidence intervals (CIs) and odds ratio (OR) with 95%CIs. The I^2^ statistic was calculated to evaluate the extent of variability attributable to statistical heterogeneity between trials. In the absence of statistical heterogeneity (I^2^≤50%), we used a fixed-effect model, otherwise we used a random-effect model for traditional meta-analysis \[[@pone.0169203.ref019]\]. To investigate the sources of heterogeneity, predefined subgroup analysis were performed: dialysis schedule and design bias. We assessed for publication bias using the Begg-Mazumdar \[[@pone.0169203.ref020]\] and Egger's test \[[@pone.0169203.ref021]\]. A non-parametric "Trim and Fill" method of assessing publication bias was applied if needed \[[@pone.0169203.ref022]\]. All tests were two tailed, and a p value of less than 0.05 was deemed statistically significant. We analyzed the data using Review Manager (Version 5.3) and STATA (Version 12.0).

Results {#sec010}
=======

Our research returned 201 results after removing duplicates, from which we collected 28 trials in our meta-analysis ([Fig 1](#pone.0169203.g001){ref-type="fig"}). After a full text review, the reasons for exclusion of literature included non-controlled trials, other intervention interference, other similar diseases, and lack of desired outcome assessments. The general characteristics of the included studies are presented in [Table 1](#pone.0169203.t001){ref-type="table"}. In this research, included studies were mainly published in Canada, China, the United States, the United Kingdom, Australia, and Turkey. The study design included eight randomized controlled trials (RCTs) \[[@pone.0169203.ref023]--[@pone.0169203.ref030]\], seven quasi-RCT \[[@pone.0169203.ref031]--[@pone.0169203.ref037]\], and thirteen observational studies \[[@pone.0169203.ref038]--[@pone.0169203.ref050]\].

![Flow diagram.\
PRISMA flow diagram.](pone.0169203.g001){#pone.0169203.g001}

10.1371/journal.pone.0169203.t001

###### Characters of included studies.

![](pone.0169203.t001){#pone.0169203.t001g}

  Author                                 Year   Country     Location or data source                                  Study design                                  Sample size(NHD)   Disease status                  Mean age (year)      Male (%)   Mean duration of dialysis (mo)[\*](#t001fn002){ref-type="table-fn"}   Dialysis session          Reported outcomes      
  -------------------------------------- ------ ----------- -------------------------------------------------------- --------------------------------------------- ------------------ ------------------------------- -------------------- ---------- --------------------------------------------------------------------- ------------------------- ---------------------- ---------------------------------------------
  Chan\[[@pone.0169203.ref038]\]         2002   Canada      Toronto General Hospital                                 Observation cohort study                      41(28)             ESRD(end-stage renal disease)   47(11)               N/A        NHD: 3.4Y; CHD: 2.8Y                                                  8--10hours, every night   4hours, 3 times/week   LVHI, BP, Hb.
  Friedman\[[@pone.0169203.ref039]\]     2002   Canada      Humber River Regional Hospital                           Cross-sectional cohort study                  54(23)             ESRD                            44(20--65)           63.0%      NHD: 100(83)M; CHD: 29(17)M                                           6--7nights/week           3 times/week           Albumin
  Heidenheim\[[@pone.0169203.ref031]\]   2003   Canada      London(Canada) Health Sciences Centre                    Prospective nonrandomized(controlled) study   45(12)             ESRD                            N/A                  N/A        18M                                                                   6 nights/week             3 times/week           QOL;
  Nesrallah\[[@pone.0169203.ref032]\]    2003   Canada      London(Canada) Health Sciences Centre                    Prospective nonrandomized(controlled) study   43(12)             ESRD                            N/A                  N/A        18M                                                                   6 nights/week             3 times/week           BP; Drug usage
  Pierratos\[[@pone.0169203.ref040]\]    2004   Canada      Humber River Regional Hospital                           Retrospective study                           88                 ESRD                            49(11)               65.0%      30(27)M                                                               3--4nights/week           \-                     QOL; LVH;
  Lindsay\[[@pone.0169203.ref033]\]      2004   Canada      London(Canada) Health Sciences Centre                    Prospective controlled study                  45(12)             ESRD                            46.7(10.5)(28--76)   67.0%      5--36M                                                                5--6 nights/week          3 times/week           BP; Mortality;
  Schwartz\[[@pone.0169203.ref041]\]     2005   Canada      Humber River Regional Hospital                           Retrospective cohort study                    95(63)             ESRD                            49.7(5.7)            68.0%      12M                                                                   5--6 nights/week          3 times/week           Hb; Drug usage
  Culleton\[[@pone.0169203.ref023]\]     2007   Canada      University of Calgary and University of Alberta          Randomized Controlled study                   52(26)             ESRD                            54.1(12.8)           62.7%      6M                                                                    6 nights/week             3 times/week           LVH; QOL; BP; Drug usage
  Johansen\[[@pone.0169203.ref042]\]     2009   U.S         United States Renal Data System database                 Observation cohort study                      1034(94)           ESRD                            46.7(17.4)           65.9%      36M                                                                   5--6 nights/week          3 times/week           Mortality; Hospitalization
  Manns\[[@pone.0169203.ref024]\]        2009   Canada      University of Calgary and University of Alberta          Randomized Controlled study                   51(26)             ESRD                            54.1(12.8)           62.7%      6M                                                                    5--6 nights/week          3 times/week           QOL
  Powell\[[@pone.0169203.ref043]\]       2009   U.K         Western Infirmary renal unit                             Case-Controlled study                         106(53)            ESRD                            51.2(15.5)           74.5%      \>12M                                                                 3 times/week              3 times/week           URR; HB; BP; Drug usage
  van Eps\[[@pone.0169203.ref044]\]      2010   Australia   Princess Alexandra Hospital                              Observation cohort study                      235(63)            ESRD                            56.5(15.1)           63.8%      12M                                                                   3.5--4 times/week         3 times/week           Side-effects; Mortality
  Lacson\[[@pone.0169203.ref045]\]       2010   U.S         Fresenius Medical Care, North America                    Case-Controlled study                         15989(655)         ESRD                            61.9(15)             53.6%      12M                                                                   3 times/week              3 times/week           Mortality; Hospitalization; QOL; BP
  Walsh\[[@pone.0169203.ref025]\]        2010   Canada      University of Calgary and University of Alberta          Randomized Controlled study                   51(26)             ESRD                            54.1(12.8)           62.7%      6M                                                                    5--6 nights/week          3 times/week           Albumin;
  Jin\[[@pone.0169203.ref034]\]          2011   China       Second Military Medical University Changzheng Hospital   Nonrandomized control study                   90(32)             ESRD                            45(10.8)             91.0%      12M                                                                   3 nights/week             3 times/week           BP; LVHI;
  Rocco\[[@pone.0169203.ref026]\]        2011   U.S         Frequent Hemodialysis Network (FHN) Trial Group          Randomized Controlled study                   87(45)             ESRD                            52.8(13.6)           65.5%      12M                                                                   6 nights/week             3 times/week           Mortality; LVH; BP; Hospitalization
  Ok\[[@pone.0169203.ref035]\]           2011   Turkey      Long Dialysis Study Group                                Prospective controlled study                  494(247)           ESRD                            45.5(13.4)           68.1%      12M                                                                   3 nights/week             3 times/week           Mortality; hospitalization; BP; Side-effect
  Overgaard\[[@pone.0169203.ref046]\]    2011   Canada      Toronto, Ontario                                         Retrospective study                           19(8)              ESRD                            52(27--68)           N/A        31M                                                                   6 nights/week             3 times/week           BP
  Rocco\[[@pone.0169203.ref027]\]        2011   U.S         Frequent Hemodialysis Network (FHN) Trial Group          Two separate randomized study                 332(87)            ESRD                            50.4(13.9)           62.0%      12M                                                                   6 nights/week             3 times/week           Mortality; LVH; QOL
  Chan\[[@pone.0169203.ref028]\]         2012   Canada      Frequent Hemodialysis Network (FHN) Trial Group          Randomized Controlled study                   87(45)             ESRD                            52.8(13.6)           65.5%      12M                                                                   6 nights/week             3 times/week           LVM;
  Demirci\[[@pone.0169203.ref036]\]      2012   Turkey      Long Dialysis Study Group                                Prospective controlled study                  120(60)            ESRD                            49(11)               69.2%      12M                                                                   3 nights/week             3 times/week           BP, LVH;
  Jin\[[@pone.0169203.ref037]\]          2012   China       Second Military Medical University Changzheng Hospital   Nonrandomized control study                   90(32)             ESRD                            45(10.8)             91.0%      12M                                                                   3 nights/week             3 times/week           BP; Hemoglobin;
  Lacson\[[@pone.0169203.ref047]\]       2012   Canada      Fresenius Medical Care, North America                    Observation cohort study                      2808(746)          ESRD                            53.8(14.2)           66.3%      24M                                                                   3 times/week              3 times/week           Mortality; PB; Albumin; Hemoglobin;
  Chan\[[@pone.0169203.ref029]\]         2013   Canada      Frequent Hemodialysis Network (FHN) Trial Group          Randomized Controlled study                   87(45)             ESRD                            52.8(13.7)           65.5%      12M                                                                   6 nights/week             3 times/week           LVH;
  Demirci\[[@pone.0169203.ref048]\]      2013   Turkey      Long Dialysis Study Group                                Prospective cohort study                      112(57)            ESRD                            48(11.8)             70.5%      12M                                                                   3 nights/week             3 times/week           BP; Albumin; Hemoglobin
  Overgaard\[[@pone.0169203.ref049]\]    2013   Canada      Toronto, Ontario                                         Retrospective study                           12(6)              ESRD                            51(27--66)           N/A        31M                                                                   6 nights/week             3 times/week           \-
  Kotanko\[[@pone.0169203.ref030]\]      2015   U.S         Frequent Hemodialysis Network (FHN) Trial Group          Randomized Controlled study                   87(45)             ESRD                            52.8(13.7)           65.5%      12M                                                                   6 nights/week             3 times/week           BP; Drug usage
  Wald\[[@pone.0169203.ref050]\]         2015   Canada      St Michael\'s Hospital and St Paul\'s Hospital           Prospective cohort study                      67(37)             ESRD                            53.8(12.2)           55.2%      12M                                                                   3 nights/week             3 times/week           LVH; Haemoglobin; BP; Drug usage

Abbreviation: NHD: nocturnal hemodialysis; ESRD: End-stage renal disease; LVH: left ventricular hypertrophy; LVHI: left ventricular hypertrophy index; BP: blood pressure; QOL: quality of life; Hb; hemoglobin; URR: Urea reduction ratio.

\*: Y: year; M: month. N/A: not available

A total number of 22,508 ESRD patients were examined. The average reported age of patients was between 40--60 years while two studies did not mention the patients' ages \[[@pone.0169203.ref031], [@pone.0169203.ref032]\]. The number of men was slightly greater than the number of women. The follow-up time duration was 6 months to 36 months. The schedule for NHD was 3 nights/week or 6--7 nights/week, and 3 times/week for CHD. The summary graph of risk of bias for each study is shown in [Fig 2](#pone.0169203.g002){ref-type="fig"}.

![Methodological quality of trials included in the meta-analysis.\
Risk of bias graph and summary.](pone.0169203.g002){#pone.0169203.g002}

In our meta-analysis, mortality results were not significantly different between the NHD group and the CHD group (OR: 0.75; 95%CI: 0.52 to 1.10; p = 0.145). For number of hospitalizations, the CHD group had significantly fewer than NHD group (OR: 1.54; 95%CI: 1.32 to 1.79; p\<0.001); in addition, there was no significant difference between the two groups in the number of infection hospitalizations (OR: 1.60; 95%CI: 0.48 to 5.35; p = 0.445).

Within cardiovascular-related variables, left ventricular hypertrophy (LVH, unit: g) and its index (LVHI, unit: g/m^2^) results both indicate the NHD group has significantly fewer occurrences than the CHD group (LVH: SMD: -0.39; 95%CI: -0.68 to -0.10; p = 0.009, LVHI: SMD: -0.64; 95%CI: -0.83 to -0.46; p\<0.001). For the control of blood pressure, systolic blood pressure results also show the NHD group is significantly better than the CHD group (Random model: SMD: -0.33; 95%CI: -0.49 to -0.18; p\<0.001, Fixed model: SMD: -0.17; 95%CI: -0.24 to -0.1; p\<0.001). The Diastolic blood pressure index also shows the NHD group is significantly better than the CHD group (Diastolic blood pressure: SMD: -.032; 95%CI: -0.48 to -0.15; p\<0.001, Mean arterial pressure: SMD: -0.69; 95%CI: -1.19 to -0.19; p = 0.007, Pulse pressure: SMD: -0.43; 95%CI: -0.75 to -0.12; p = 0.007).

For uremia-related variables, the concentration of serum albumin of the NHD group was significantly greater than the CHD group (SMD: 0.89; 95%CI: 0.41 to 1.36; p\<0.001); the concentration of serum hemoglobin of the NHD group was also significantly greater than the CHD group (SMD: 0.42; 95%CI: 0.05 to 0.78; p = 0.025). The urea clearance index in the NHD group was significantly higher than the CHD group (SMD: 2.61; 95%CI: 1.76 to 3.46; p\<0.001), and urea reduction ratio was also better in the NHD group (SMD: 1.39; 95%CI: 0.49 to 2.30; p = 0.003).

For the assessment of quality of life (QOL), NHD treatment only had significantly improved results for the patient in the SF36-Physical Components Summary (SMD: 0.43; 95%CI: 0.26 to 0.60; p\<0.001). The results of the European QOL (SMD: -0.34; 95%CI: -1.83 to 1.14; p = 0.651) and the SF36-Mental Components Summary (SMD: 0.11; 95%CI: -0.07 to 0.28; p = 0.226) showed no significant difference between groups. In the patients' drug usage assessment, the anti-hypertensive drug dosage in the NHD group was significantly lower than in the CHD group after dialysis (SMD: -0.48; 95%CI: -0.91 to -0.05; p = 0.005). However, the dosage of EPO was not different between groups (SMD: -0.23; 95%CI: -0.60 to 0.14; p = 0.222). In our assessment of the side effects of dialysis, the bacteremia (OR: 1.89; 95%CI: 0.96 to 3.74; p = 0.067) and septic (OR: 2.58; 95%CI: 0.73 to 9.16; p = 0.141) both showed no difference between groups.

Performing subgroup analysis, it was found that treatment with nocturnal dialysis 3 times/week yielded a significantly lower mortality rate than the control group (OR: 0.56; 95%CI: 0.34 to 0.92; p = 0.021; I^2^ = 74.8%), while the use of dialysis \>3times/week yielded no significant differences (OR: 1.47; 95%CI: 0.68 to 3.19; p = 0.334; I^2^ = 30.6%). Through subgroup analysis of study designs it was discovered that randomized controlled trials and non-randomized controlled trials showed no significant differences in results (RCTs: OR: 0.98; 95%CI: 0.29 to 3.34; p = 0.977; Non-RCTs: OR: 0.73; 95%CI: 0.48 to 1.11; p = 0.140) ([Table 2](#pone.0169203.t002){ref-type="table"}). Only in non-RCT researches, haemoglobin concentration showed significant difference between nocturnal dialysis and control group (SMD: 0.49; 95%CI: 0.10 to 0.88; p = 0.013). In the drug usage assessment, anti-hypertensive drug dosage in patients received more than 3 times per week nocturnal hemodialysis subgroup was significant less than CHD group (SMD: -0.64; 95%CI: -0.92 to -0.37; p\<0.001), and in RCT design studies the anti-hypertensive drug dosage in the NHD group was significantly lower than in the CHD group (SMD: -0.64; 95%CI: -0.92 to -0.37; p\<0.001). In subgroup analysis, the EPO dosage of 3 times/week subgroup showed significant less than CHD group (SMD: -0.45; 95%CI: -0.83 to -0.06; p = 0.022). However, the heterogeneity was not obviously reduced in all subgroup analysis.

10.1371/journal.pone.0169203.t002

###### Subgroup analysis of nocturnal and conventional hemodialysis on ESRD patients.
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  Outcome                    Subgroup         No. of trials   OR/SMD   LCI     UCI        p value    Heterogeneity   p for Heterogeneity
  -------------------------- ---------------- --------------- -------- ------- ---------- ---------- --------------- ---------------------
  Mortality                  \>3 night/week   5               1.47     0.68    3.19       0.334      30.60%          0.217
  3 night/week               6                0.56            0.34     0.92    0.021      74.80%     0.001           
  Randomized design          3                0.98            0.29     3.34    0.977      0%         0.552           
  Nonrandomized design       8                0.73            0.48     1.11    0.14       73.10%     0.001           
  Systolic blood pressure    \>3 night/week   4               -0.48    -0.71   -0.25      \< 0.001   0%              0.911
  3 night/week               6                -0.27           -0.44    -0.09   0.003      47.20%     0.092           
  Randomized design          3                -0.47           -0.71    -0.22   \< 0.001   0%         0.086           
  Nonrandomized design       7                -0.29           -0.46    -0.11   0.001      45.90%     0.803           
  Albumin                    \>3 night/week   1               7.26     5.77    8.76       \< 0.001   \-              \-
  3 night/week               5                0.4             0.21     0.59    \< 0.001   67.70%     0.015           
  Haemoglobin                \>3 night/week   3               1.2      -1.38   3.77       0.363      98%             \< 0.001
  3 night/week               7                0.17            -0.013   0.36    0.068      70%        0.003           
  Randomized design          1                -0.3            -0.85    0.26    0.293      \-         \-              
  Nonrandomized design       9                0.49            0.1      0.88    0.013      94%        \< 0.001        
  Urea clearance index       \>3 night/week   2               7.12     -1.97   16.21      0.125      97.20%          \< 0.001
  3 night/week               3                1.83            1.05     2.61    \< 0.001   93.90%     \< 0.001        
  Anti-blood pressure drug   \>3 night/week   2               -0.64    -0.92   -0.37      \< 0.001   0%              0.807
  3 night/week               2                -0.32           -1.23    0.6     0.498      88.10%     0.004           
  Randomized design          2                -0.64           -0.92    -0.37   \< 0.001   0%         0.807           
  Nonrandomized design       2                -0.32           -1.23    0.6     0.498      88.10%     0.004           
  EPO usage                  \>3 night/week   4               0        -0.75   0.75       0.994      86.30%          \< 0.001
  3 night/week               3                -0.45           -0.83    -0.06   0.022      74.80%     0.019           
  Randomized design          1                0.18            -0.27    0.63    0.434      \-         \-              
  Nonrandomized design       6                -0.3            -0.7     0.09    0.132      81.50%     \< 0.001        

Abbreviations: ESRD: End-stage Renal Disease; OR: Odds ratio; SMD: Standard Mean Difference; LCI: Lower Confidence interval; UCI: Upper Confidence interval.

There was publication bias was found in systolic blood pressure results ([Table 3](#pone.0169203.t003){ref-type="table"}, Begg'test, p = 0.592; Egger's test, p = 0.001). However, no other publication bias was found. After correction of the results with "Trim and Fill" method the conclusion was not changed.

10.1371/journal.pone.0169203.t003

###### Results of treatment effects of NHD versus CHD on end-stage renal failure patients.
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  Outcomes                                    No. of trials   Effect size   Value     LCI      UCI     P value   Heterogeneity   P for Heterogeneity   Model    Begg's test   Egger's test   Favors
  ------------------------------------------- --------------- ------------- --------- -------- ------- --------- --------------- --------------------- -------- ------------- -------------- -----------
  Mortality                                                                                                                                                                                  
   Mortality                                  11              OR            0.75      0.52     1.1     0.145     63.40%          0.002                 Random   0.533         0.87           Equal
  Hospitalization                                                                                                                                                                            
   Number of Hospitalization                  2               OR            1.54      1.32     1.79    \<0.001   0%              0.549                 Fixed    \-            \-             CHD group
   Number of Infection hospitalization        1               OR            1.6       0.48     5.35    0.445     \-              \-                             \-            \-             Equal
  Cardiovascular-associated variables                                                                                                                                                        
   Left ventricular hypertrophy (g)           3               SMD           -0.39     -0.68    -0.1    0.009     0%              0.74                  Fixed    1             0.874          NHD group
   Left ventricular hypertrophy index(g/m2)   5               SMD           -0.64     -0.83    -0.46   \<0.001   0%              0.837                 Fixed    0.806         0.669          NHD group
   Systolic blood pressure                    10              SMD           -0.33     -0.49    -0.18   \<0.001   48.50%          0.042                 Random   0.592         0.001          NHD group
  -0.17                                       -0.24           -0.1          \<0.001   48.50%   0.042   Fixed     0.592           0.001                                                       
   Diastolic blood pressure                   7               SMD           -0.32     -0.48    -0.15   \<0.001   0%              0.967                 Fixed    0.368         0.295          NHD group
   Mean arterial pressure                     2               SMD           -0.69     -1.19    -0.19   0.007     0%              0.646                 Fixed    \-            \-             NHD group
   Pluse pressure                             2               SMD           -0.43     -0.75    -0.12   0.007     0%              0.326                 Fixed    \-            \-             NHD group
  Uremia-associated variables                                                                                                                                                                
   Albumin                                    6               SMD           0.89      0.41     1.36    \<0.001   94.70%          \<0.001               Random   0.133         0.186          NHD group
   Haemoglobin                                10              SMD           0.42      0.05     0.78    0.025     93.40%          \<0.001               Random   0.721         0.248          NHD group
   Urea clearance index                       5               SMD           2.61      1.76     3.46    \<0.001   94.60%          \<0.001               Random   0.462         0.757          NHD group
   Urea Reduction ratio(%)                    3               SMD           1.39      0.49     2.3     0.003     91.60%          \<0.001               Random   1             0.698          NHD group
  QOL                                                                                                                                                                                        
   European Quality of life                   2               SMD           -0.34     -1.83    1.14    0.651     92.30%          \<0.001               Random   \-            \-             Equal
   SF36(Mental Components Summary)            2               SMD           0.11      -0.07    0.28              0%              0.605                 Fixed    \-            \-             Equal
   SF36(Physical Components Summary)          2               SMD           0.429     0.258    0.6     \<0.001   32.50%          0.224                 Fixed    \-            \-             NHD group
  Drug usage                                                                                                                                                                                 
   Anti-blood pressure drug                   4               SMD           -0.48     -0.91    -0.05   0.03      76.60%          0.005                 Random   0.734         0.585          NHD group
   EPO usage                                  7               SMD           -0.23     -0.6     0.14    0.222     82.20%          \<0.001               Random   0.23          0.302          Equal
  Side Effect                                                                                                                                                                                
   Bacteremia                                 2               OR            1.89      0.96     3.74    0.067     4.10%           0.307                 Fixed    \-            \-             Equal
   Septic                                     2               OR            2.58      0.73     9.16    0.141     85.80%          0.008                 Random   \-            \-             Equal

Abbreviation: SMD: Standardized Mean Difference; OR: odds ratio; LCI: Lower confidence interval; UCI: Upper confidence interval; NHD: Nocturnal Hemodialysis; CHD: Conventional Hemodialysis

Discussions {#sec011}
===========

In this review, we analyzed the effects of NHD versus CHD in the treatment of ESRD. Our analysis included 28 trials with 22,508 patients. Our results demonstrate that NHD and CHD are similar in mortality and side-effects, and that NHD is superior to CHD in cardiovascular-associated and uremia-associated markers and in QOL and drug usage. CHD is relatively better than NHD for number of hospitalizations. In general, NHD has more advantages in clinical applications for ESRD patients.

In previously published meta-analyses, the results assessment was not comprehensive. Hui MJ et al. studied the effects of long-time dialysis in daytime or nighttime on survival rate compared to that of conventional hemodialysis \[[@pone.0169203.ref016]\]. Results showed that the survival rate of patients using prolonged hemodialysis was significant higher than those using conventional hemodialysis; however, residual confounders, which include the patients' age, sex, presence of diabetes, and catheter use, interferes with the results in observational studies. This study included literatures with lower design quality while not having a comprehensive assessment index. Our research included more high quality design articles to find that nocturnal dialysis does not significant improve the mortality of patients; however, subgroup analysis of treatment 3times/week showed reduced mortality rates. This may be due to the fact that the study used patients with relatively mild uremic symptoms while further study is needed to draw conclusions for the specific causes. Julia Thumfart et al. evaluated the effect of intensified nocturnal hemodialysis on ESRD patients compared to conventional hemodialysis in 2014 \[[@pone.0169203.ref015]\]. That study found that intensified hemodialysis could significantly improve the patients' blood pressure, uremia-associated variables, and psychosocial variables, and could reduce the usage of antihypertensive and phosphate binders. However, there was no assessment of patients' mortality and QOL. Our research supports the evidence that intensified hemodialysis could improve cardiovascular-related and uremia-related indicators; we also defined that nocturnal dialysis could improve the patients' QOL. Paweena Susantitaphong et al. assessed the effects of frequent nocturnal hemodialysis on ESRD patients using the indicators of left ventricular mass and cardiovascular mortality in 2012 \[[@pone.0169203.ref014]\]. Unfortunately, this research had a paucity of randomized controlled trials. The results supported that frequent or extend hemodialysis could improve cardiac morphology and function; however the outcome of long-term clinical application was limited. Our study includes a longer follow-up period of up to 36 months and RCTs. Our results support the above conclusion and consider long-time nocturnal hemodialysis as beneficial for cardiovascular and uremia-related indicators.

It is very common for cardiovascular complications to occur in long-term hemodialysis patients, including hypertension, coronary heart disease, arrhythmia, and heart failure. Cardiac vascular disease events like cerebrovascular accident, ischemic heart disease, congestive cardiac failure, peripheral vascular disease are also much more prevalent in the chronic kidney disease population. Furthermore, cardiovascular complications are the most common causes of death in ESRD patients and the mortality rate for dialysis patients is up to 10--30 times higher than the matched population \[[@pone.0169203.ref051]\]. The high mortality indicates the effect of drugs to reduce the incident of cardiovascular disease is not ideal. Therefore, researchers presume the incidence of cardiovascular disease in dialysis patients may have a special pathophysiological process.

There are two parallel factors which may contribute to cardiovascular disease in ESRD patients. The first is a change of cardiac morphological including LVH and left ventricular (LV) dysfunction caused by mechanical or hemodynamic overload and the second being the change of vasculature including atherosclerosis and vascular calcification. These two factors can eventually result in cardiomyopathy and arterial thrombosis \[[@pone.0169203.ref052]\]. Uremia-related hyperphosphatemia, high calcium and phosphorus deposition, and hyperparathyroidism may be the direct reason for vascular calcification in ESRD patients. Currently it is popular to assess the patient's dialysis schedule with cardiovascular-related symptoms, in which left ventricular hypertrophy is an important predictor of cardiovascular side effects. Thus, many RCTs use left ventricular mass (LVM) as the primary outcome \[[@pone.0169203.ref023], [@pone.0169203.ref028]\]. Our results show nocturnal dialysis have positive effects on the prevention of cardiovascular disease, which can enhance blood pressure control and reduce serum phosphate, hence reducing the risk of cardiovascular disease.

Although our study shows nocturnal dialysis has a great positive effect on ESRD patients, this approach also has a higher failure rate. For example, a 12 month follow-up period study pointed out that the technique's survival rate is 79.2% \[[@pone.0169203.ref045]\]; a 24 months follow-up period study showed the technique's survival rate by then was only 24.93% \[[@pone.0169203.ref047]\], meaning about 3/4 of ESRD patients were unable to continue nocturnal hemodialysis treatment. These studies found that the reasons of technique failure included infection, catheter dysfunction, and psychosocial problems in the early stage and ultrafiltration -failure and catheter-related infection in later stages. Therefore further research is needed to look into ways of increasing the technique's survival rate on patients with high frequency nocturnal dialysis by improving technology and reducing complications.

We comprehensively evaluated the outcome measurements of nocturnal dialysis for ESRD, but still our study had several limitations. First, we did not have specific individual data for all the trials and thus our statistical approach was done at a study level. Second, the quality of included trials was relatively low, although this review included many outcome measures, single measure conclusions were considered from small sample studies of low quality. Third, there was heterogeneity in several outcomes among included trials. Finally, we were not able to use subgroup analysis or meta-regression to reduce the heterogeneity because there was a lack of trials using a single medicine.

Nocturnal hemodialysis and conventional hemodialysis perform similarly in ESRD patients' mortality and side-effects. In cardiovascular-associated and uremia-associated results NHD is superior to CHD; and in QOL and drug usage NHD intervention is relatively better than CHD. For number of hospitalizations, CHD was relatively better than NHD. In general, NHD has more advantages in clinical application for ESRD patients.
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